Mangoceuticals Q3 2023 Earnings Report $2.52 -0.10 (-3.82%) (As of 10:49 AM ET) Earnings History Mangoceuticals EPS ResultsActual EPS-$24.75Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMangoceuticals Revenue ResultsActual Revenue$0.25 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMangoceuticals Announcement DetailsQuarterQ3 2023Date10/27/2023TimeN/AConference Call ResourcesMGRX Earnings History BITCOIN (Ad)Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this...Watch this short video Mangoceuticals Earnings HeadlinesMangoceuticals (NASDAQ:MGRX) Enters into Securities Purchase Agreements with Institutional Accredited InvestorsDecember 27 at 6:08 AM | americanbankingnews.comMangoceuticals Expands with Patent Acquisition in NutraceuticalsDecember 20, 2024 | markets.businessinsider.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 27, 2024 | Brownstone Research (Ad)Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations PatentDecember 19, 2024 | globenewswire.comMangoceuticals, Inc. (MGRX) Latest Stock News & Headlines - Yahoo FinanceDecember 6, 2024 | finance.yahoo.comMangoceuticals initiates investigation into potential stock manipulationDecember 5, 2024 | markets.businessinsider.comSee More Mangoceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email. Email Address About MangoceuticalsMangoceuticals (NASDAQ:MGRX) develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.View Mangoceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
